Dr. Murphy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1959 Ne Pacific St
Box 357110
Seattle, WA 98195Phone+1 206-598-6131Fax+1 206-598-6189
Education & Training
- University of WashingtonResidency, Pathology-Anatomic and Clinical, 2008 - 2011
- Northwestern University The Feinberg School of MedicineClass of 2008
Certifications & Licensure
- WA State Medical License 2008 - 2026
- American Board of Pathology Pathology - Clinical
Publications & Presentations
PubMed
- WHO malaria nucleic acid amplification test external quality assessment scheme: results of eleven distributions over 6 years.Rebecca M Thomson, Jane A Cunningham, Michelle M Gatton, Sean C Murphy, Maria de la Paz Ade
Malaria Journal. 2025-03-23 - Distinguishing new from persistent infections at the strain level using longitudinal genotyping data.William A Nickols, Philipp Schwabl, Amadou Niangaly, Sean C Murphy, Peter D Crompton
Biorxiv. 2025-02-08 - Identifying Plasmodium P36 and P52 antigens for coadministration with circumsporozoite protein to enhance vaccine efficacy.Naveen Yadav, Anya C Kalata, Rebekah A Reynolds, Andrew Raappana, D Noah Sather
NPJ Vaccines. 2024-12-06
Journal Articles
- Screening for Pfhrp2/3-Deleted Plasmodium Falciparum, Non-Falciparum, and Low-Density Malaria Infections by a Multiplex Antigen AssaySean Murphy, MD, The Journal of Infectious Diseases
- Prime-and-Trap Malaria Vaccination to Generate Protective CD8+ Liver-Resident Memory T CellsSean Murphy, MD, The Journal of Immunology
- Plasmodium 18S rRNA of Intravenously Administered Sporozoites Does Not Persist in Peripheral BloodSean C Murphy, BioMed Central
Press Mentions
- Optimizing Immunization with Sanaria® PfSPZ-CVac Malaria VaccineJune 8th, 2021
- Getting Sick for the Sake of Medical ResearchApril 7th, 2021
- Kids Desperate for Inpatient Psych Care Have Few Options in WAJuly 27th, 2020
- Join now to see all
Grant Support
- Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposureOREGON HEALTH & SCIENCE UNIVERSITY2022–2027
- Development of an oral liver-targeted prime-and-trap malaria vaccineUNIVERSITY OF WASHINGTON2020–2025
- Phase II STTR development of an intranasal/oral Spirulina-based PfCSP malaria vaccine.LUMEN BIOSCIENCE, INC.2018–2025
- Phase II STTR development of an intranasal/oral Spirulina-based PfCSP malaria vaccine.LUMEN BIOSCIENCE, INC.2018–2025
- Phase II STTR development of an intranasal/oral Spirulina-based PfCSP malaria vaccine.LUMEN BIOSCIENCE, INC.2018–2025
- Phase II STTR development of an intranasal/oral Spirulina-based PfCSP malaria vaccine.LUMEN BIOSCIENCE, INC.2018–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: